Bringing the Parisian café to American homes
PARIS, June 2, 2025 /PRNewswire/ -- Maxim's de Paris has announced its entry into the competitive US home coffee market with the launch of 'Seine X' - the world's first intelligent semi-automatic three-in-one variable pressure espresso machine, a category-defining innovation in the premium home coffee segment. The cutting-edge machine blends intelligent technology, personalized features, and classic French design to instil le joie de vivre from the comfort of the home.
Inspired by the iconic French car from the 1950s, the 'Simca 9', it took four years of R&D to create Seine X. Industry insiders have called the coffee maker a 'game-changer' in the home coffee machine category.
Oscar, CEO of Maxim's Espresso said: "I'm delighted to be sharing our new baby with the world. Maxim's has set a high watermark with its Michelin food, but we want to show the world that we take coffee seriously too."
The Seine X's patented MPF Multi-Frequency Stable Pressure Control™, allows the user to adjust the pressure of their espresso between a range of 3 to 15 bars. By tweaking the pressure, the user unlocks a myriad of complex flavors in every bean—ideal for experimenting with light roasts to dark blends.
A major selling point is the 'super-steam' wand, which can produce professional dry steam making effortless cappuccinos, flat whites and cortados. The integrated thermometer allows you to monitor the temperature of the milk in real time.
"Maxim's machine is a game changer, it's one of the most complete home espresso machines I've tested", said Elida, a former judge for the World Barista Championships: "It's possible the best espressos in the world can now be found at home."
For those who appreciate the finer things—from an aged Bordeaux to hotels with a view—Maxim's now invites you to elevate your morning with an espresso that rivals the quality of its cuisine.
Maxim's has been synonymous with French elegance, culinary excellence, and the art of sophisticated living since 1893. Born as a Parisian restaurant on the iconic Rue Royale, we've been offering the world a taste of Parisian luxury for more than a century. For more information about Maxim's Seine X, visit maximsespresso.com.
Media Contact
Eric Wilson
Maxim's de Paris
hi@maximsespresso.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Maxim's de Paris expands to the US market with cutting-edge 'Seine X' home coffee machine
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
